Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Congress passes FDA act that would do away with animal testing requirement  

By Brian Buntz | December 29, 2022

Mouse

[Photo by Pixabay]

The U.S. House has approved the FDA Modernization Act 2.0, which would end the animal testing requirement for new drugs and biosimilars.

The bill doesn’t completely ban testing on animals but enables drug developers to use alternatives when feasible.

In September, the U.S. Senate passed the FDA Modernization Act 2.0, S.5002.

The new policy, known as the Reducing Animal Testing Act, was attached to the $1.7 trillion omnibus spending bill.

Before Christmas, Biden vowed to sign the bill as soon as it reached his desk.

Section 3209 of the bill amends the Federal Food, Drug, and Cosmetics Act (FFDCA) to specify “nonclinical tests” instead of “preclinical tests.” It also swaps the term “animal” for “nonclinical tests” and adds new text identifying that “nonclinical tests” may incorporate human-relevant testing methods. Those methods may include cell-based assays, bioprinted models and microphysiological systems, including organ-chips or computer models.

A growing number of companies are working on developing AI-models that could reduce or replace the need for animal testing in some situations in the coming years.

The federal mandate for animal testing has been U.S. law since 1938.

The FDA Modernization Act 2.0 won support from more than 200 organizations. Generics giant Teva was the only pharma backer.

The omnibus spending bill also had a provision to earmark $5 million for an FDA New Alternative Methods Program designed to curb animal testing.

The original FDA Modernization Act 2.0 spending bill was introduced by Senators Dr. Rand Paul (R-KY) and Cory Booker (D-NJ).

It was based on S.2952, the FDA Modernization Act of 2021.

Earlier in December, New York Governor Kathy signed into law a provision that blocks the sale of cosmetics that had been recently tested on animals. A total of 10 U.S. states have passed such legislation.


Filed Under: Drug Discovery, Drug Discovery and Development
Tagged With: animal testing, FDA Modernization Act 2.0
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE